Sharp invests $100m in US and EU manufacturing and packaging facilities
Charlie Blackie-Kelly | October 27, 2025 | News story | Manufacturing and Production |Â Â EU, Sharp Services, US, manufacturing and packagingÂ
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across its US and European facility network.
According to the company, the investment reflects growing market demand for the assembly and packaging of pre-filled syringes (PFSs) and associated services. The expansion programme will increase Sharp’s capacity to support existing clients and products while enabling future growth opportunities.
In Europe, funding will enhance Good Manufacturing Practice (GMP) production capabilities for vial labelling, syringe assembly and injectable packaging at Sharp’s Netherlands facility, which is scheduled to come online in 2026. At its site in Belgium, the investment will support a warehouse expansion, adding a new syringe blistering production suite and additional ambient and cold-chain storage capacity.
In the United States, the programme includes the installation of a 2-8°C production room with refrigeration and a -15 to -25°C walk-in freezer at the company’s Bethlehem, PA, site, alongside two new capsule-filling machines and an oral solid dose (OSD) blister packaging line. These are expected to be operational by the end of 2025.
At Sharp’s Lee, MA, facility, a $28m expansion will install a fourth isolator-based sterile filling line with lyophilisation capability, along with further infrastructure upgrades to increase capacity.
Additionally, the company’s Allentown campus will add new PFS assembly, labelling and packaging lines, a vial labeller and high-speed cartoner, a mid-speed bottling and packaging line for OSD products, and automated pouch filling lines for powders and OSD formats.
Kevin Orfan, President & CEO of Sharp, commented: “These multi-site investments at Sharp reflect our ongoing commitment to support the evolving needs of our pharma and biopharma clients in each of our core businesses. We are strengthening our service offerings across our entire network to provide more capacity, new capabilities and greater efficiency.”
Related Content
Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s …
Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours
The START Center for Cancer Research has dosed the first US participant in Moderna’s phase …
EU approval granted for rare kidney disease treatment
The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ …
